Dewey Curtis W, Cerda-Gonzalez Sofia, Levine Jonathan M, Badgley Britton L, Ducoté Julie M, Silver Gena M, Cooper Jocelyn J, Packer Rebecca A, Lavely James A
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
J Am Vet Med Assoc. 2009 Dec 15;235(12):1442-9. doi: 10.2460/javma.235.12.1442.
To assess tolerability and short-term efficacy of oral administration of pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with poorly controlled suspected idiopathic epilepsy.
Open-label, noncomparative clinical trial.
11 client-owned dogs suspected of having idiopathic epilepsy that was inadequately controlled with phenobarbital, potassium bromide, or a combination of these 2 drugs.
Dogs were treated with pregabalin (3 to 4 mg/kg [1.4 to 1.8 mg/lb], PO, q 8 h) for 3 months. Number of generalized seizures in the 3 months before and after initiation of pregabalin treatment was recorded. Number of responders (>or= 50% reduction in seizure frequency) was recorded, and seizure frequency before and after initiation of pregabalin treatment was compared by use of a nonparametric Wilcoxon signed rank test.
Seizures were significantly reduced (mean, 57%; median, 50%) after pregabalin administration in the 9 dogs that completed the study; 7 were considered responders with mean and median seizure reductions of 64% and 58%, respectively. Adverse effects for pregabalin were reported in 10 dogs. Mean and median plasma pregabalin concentrations for all dogs were 6.4 and 7.3 microg/mL, respectively.
Pregabalin may hold promise as a safe and effective adjunct anticonvulsant drug for epileptic dogs poorly controlled with the standard drugs phenobarbital or potassium bromide. Adverse effects of pregabalin appeared to be mild. Additional studies with larger numbers of dogs and longer follow-up intervals are warranted.
评估口服普瑞巴林作为苯巴比妥、溴化钾或苯巴比妥与溴化钾联合用药的辅助药物，用于治疗疑似特发性癫痫控制不佳犬的耐受性和短期疗效。
开放标签、非对照临床试验。
11只客户拥有的疑似患有特发性癫痫的犬，其癫痫发作无法用苯巴比妥、溴化钾或这两种药物的联合用药得到充分控制。
犬接受普瑞巴林治疗（3至4mg/kg[1.4至1.8mg/lb]，口服，每8小时一次），持续3个月。记录普瑞巴林治疗开始前后3个月内全身性癫痫发作的次数。记录有反应者（癫痫发作频率降低≥50%）的数量，并使用非参数威尔科克森符号秩检验比较普瑞巴林治疗开始前后的癫痫发作频率。
完成研究的9只犬在服用普瑞巴林后癫痫发作显著减少（平均减少57%；中位数减少50%）；7只犬被视为有反应者，平均和中位数癫痫发作减少分别为64%和58%。10只犬报告了普瑞巴林的不良反应。所有犬的平均和中位数血浆普瑞巴林浓度分别为6.4和7.3μg/mL。
对于使用标准药物苯巴比妥或溴化钾控制不佳的癫痫犬，普瑞巴林有望成为一种安全有效的辅助抗惊厥药物。普瑞巴林的不良反应似乎较轻。有必要进行更多犬只参与且随访时间更长的进一步研究。
